Inclusion Criteria:

          -  Histologically confirmed NSCLC;

          -  Locally advanced and/or metastatic stage IV NSCLC (according to American Joint
             Committee on Cancers) or recurrent NSCLC);

          -  Patients without activating EGFR mutation or ALK rearrangement and ROS1 fusions.

          -  Subject has provided a formalin-fixed tumor-tissue sample of a tumor-lesion biopsy,
             either at the time of or after metastatic disease was diagnosed AND from a site not
             previously irradiated to assess for PDL1 status. Archived tissue may be acceptable or
             PDL1 status known;

          -  Progressive disease after first-line platinum-doublet-based chemotherapy according to
             RECIST V.1.1 with measurable lesion (RECIST V1.1);

          -  Age ≥18 years, either sex;

          -  Eastern Collaborative Oncology Group Performance status (ECOG PS) 0, 1 or 2;

          -  Life expectancy exceeds 12 weeks;

          -  No history of other malignancy within the last 5 years, except for adequately treated
             carcinoma in situ of the cervix or basal cell or spinocellular carcinoma of the skin;

          -  Adequate organ function, demonstrated by the following laboratory results within 3
             weeks prior to teatment: Normal hepatic function: bilirubin <1.5 × normal (N), Alanine
             aminotransferase and Aspartate aminotransferase <2.5 × N or <5 × N if liver metastasis
             is present;

          -  Normal renal function (calculated creatinine clearance ≥45 mL/min);

          -  Normal calcemia;

          -  Normal hematological function (polynuclear neutrophils >1.5 G/L, platelets >100 G/L
             and hemoglobin>8g/dl);

          -  Women of child-bearing potential must use effective contraception;

          -  Men might be surgically sterile or accept to use an effective contraceptive procedure
             during and until 6 months after the treatment;

          -  Written informed consent to participate in the study

          -  Patient with social insurance

        Exclusion Criteria:

          -  ECOG PS >2;

          -  Known hypersensitivity to immunotherapy;

          -  Small-cell lung cancer, bronchioloalveolar cancer, neuroendocrine cancer;

          -  Tumor harbors EGFR-sensitizing (activating) mutations or ALK translocations or ROS1
             fusions and that justify treatment with targeted therapy ;

          -  Chemotherapy, hormonotherapy, immunotherapy or tyrosine-kinase inhibitors within the
             past 4 weeks prior to treatment with the trial drug;

          -  Radiotherapy (except bone or brain) within the past 3 months prior to baseline
             imaging;

          -  Medical contraindication to oral vinorelbine;

          -  Persistence of clinical adverse events with a grade > 2 related to prior treatment;

          -  Active brain metastases (e.g. stable for <4 weeks, no adequate previous radiotherapy,
             symptomatic, requiring anticonvulsants or corticosteroids)

          -  Concurrent radiotherapy, except for palliative bone irradiation.

          -  Other concurrent severe illnesses (congestive heart failure, unstable angina,
             significant arrhythmia or myocardial infarction <12 months before study entry);

          -  Active or prior documented autoimmune or inflammatory disorders;

          -  Active B hepatitis, HIV infection …;

          -  Psychiatric or neurological disorders preventing the patient from understanding the
             nature of the trial;

          -  Grade-3 peripheral neuropathy;

          -  Uncontrolled infection;

          -  Interstitial lung disease or pneumonitis requiring steroid management;

          -  Corticosteroid therapy exceeding 10 mg/day;

          -  Other severe organic disorders not allowing inclusion in the trial;

          -  Malabsorption syndrome;

          -  Pregnancy or breast-feeding;

          -  Follow-up not possible; and incarcerated or institutionalized patients.